Maturation of dendritic cells induced by nano-liposomes containing imiquimod

Asian Biomedicine

Volumn 2, Issue 3, 2008, Pages 233-239

  Homhuan, Atthachai ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Dendritic cells; Imiquimod; Liposomes; Phenotypic maturation

Indexed keywords

B7 ANTIGEN; CATION; CD86 ANTIGEN; IMIQUIMOD; LIPOPOLYSACCHARIDE; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL LINE; CELL MATURATION; CELL STIMULATION; DENDRITIC CELL; DRUG FORMULARY; MOUSE; NANOENCAPSULATION; NONHUMAN; PHENOTYPE;

EID: 70349305714     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 2002;1589:1-13.
2. (Pubitemid 39421058) Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488-96.
3. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines. 2007;6:835-47.
4. (Pubitemid 34141451) Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 My D88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
5. Martn-Garca RF. New insights into imiquimod's mechanisms of action. J Drugs Dermatol. 2004;3:247-9.
6. (Pubitemid 43023259) Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, et al. The TLR-7 agonists, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2005;176:157-64.
7. (Pubitemid 43238279) Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine. 2006;24:1958-65.
8. (Pubitemid 41820430) Donnelly R, McCarron PA, Zawislak AA, Woolfson AD. Design and physicochemical characterisation of a bioadhesive patch for dose-controlled topical delivery of imiquimod. Int J Pharm. 2006;307:318-25.
9. Lian T, Ho PJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2000;90:667-80.
10. Kersten GFA, Crommelin DJA. Liposomes and ISCOMs. Vaccine. 2003;21:915-920.
11. (Pubitemid 44415497) Altin JG, Parish CR. Liposomal vaccines - targeting the delivery of antigen. Methods. 2006;40:39-52.
12. (Pubitemid 33136872) Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem. 2001;12:1005-11.
13. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocytes/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
14. (Pubitemid 35365166) Fogel M, Long JA, Thompson PJ, Upham JW. Dendritic cell maturation and IL-12 synthesis induced by the synthetic immune-response modifier S-28463. J Leukoc Biol.2002;72:932-8.
15. (Pubitemid 43849034) Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol. 2006;176:7336-45.
16. (Pubitemid 27460839) Ishii N, Fukushima J, Kaneko T, Okada E, Tani SI, Tanaka K, et al. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1997;13:1421-8.
17. (Pubitemid 29531282) Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 1999;6:1867-75.
18. (Pubitemid 32852574) Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol. 2001;167:3324-8.
19. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol. 1999;163:1552-61.